RAPT Therapeutics (RAPT) AI Stock Analysis

• Market Cap: $134.93M
• Dividend Yield: N/A
• Average Volume (3M): 106.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.69
• Revenue Growth: N/A
• EPS Growth: -2.29%
• Country: US
• Employees: 67
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.64
• Shares Outstanding: 16,536,085
• 10 Day Avg. Volume: 128,580
• 30 Day Avg. Volume: 106,152
• PEG Ratio: -6.53
• Price to Book (P/B): 2.63
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.00
• Enterprise Value/Market Cap: 3.89
• Enterprise Value/Revenue: 49.68
• Enterprise Value/Gross Profit: -1.72K
• Enterprise Value/Ebitda: -1.06
• 1Y Price Target: $32.00
• Price Target Upside: 298.51% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 39 Underperform
• Price Target: ―

RAPT Therapeutics' overall stock score reflects significant challenges, primarily due to its inability to generate revenue and consistent operational losses. The strong equity position in the balance sheet is a positive, but technical indicators suggest a continued downward trend. The negative valuation metrics further highlight the risks associated with the stock.

Positive Factors

Development Strategy

RAPT was granted worldwide rights excluding mainland China, Hong Kong, Macau and Taiwan to develop and commercialize RPT904, offering potential market expansion.

Financial Performance

RAPT reported better than expected net loss per share, which was ($0.08) versus the consensus of ($0.14).

Financial Stability

The company ended the quarter with a strong cash position of approximately $179 million.

Negative Factors

Analyst Rating

Analyst reiterates an Underweight rating on RAPT shares given that RPT904 needs time and data to be better appreciated by the Street.

Clinical Trial Risks

Risks include negative results from POC studies in China, failure of the U.S. Phase 2b trial of RPT904 in food allergy, and potential failure to secure U.S. approval.

Market Competition

RAPT anticipates pricing erosion of 40% due to Xolair patent expiration and entry of biosimilar products, despite a potential price premium for RPT904.

RAPT Therapeutics Business Overview & Revenue Model

Company Description

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

How the Company Makes Money

RAPT Therapeutics generates revenue primarily through strategic collaborations and partnerships with other pharmaceutical companies, as well as government grants and funding for its research initiatives. The company may also license its proprietary technology and intellectual property to other firms, providing another revenue stream. As RAPT advances its product candidates through clinical trials and towards potential commercialization, it anticipates generating revenue from the sale of its therapies upon obtaining necessary regulatory approvals.

RAPT Therapeutics Financial Statement Overview

Summary

RAPT Therapeutics faces significant challenges, primarily due to its inability to generate revenue and consistent operating losses. While the balance sheet shows a strong equity base and low leverage, the company's cash flow and income statement highlight sustainability concerns.

Income Statement

RAPT Therapeutics has consistently reported negative net income and EBIT over the past years, indicating ongoing operational challenges. The company has not generated any revenue in recent years, which is a concern for sustainability. The lack of revenue and consistent losses contribute to a low score for the income statement.

Balance Sheet

The balance sheet shows a relatively strong equity position with a low debt-to-equity ratio, indicating conservative leverage. However, the lack of revenue generation poses a risk to the sustainability of the company's financial health. The equity ratio is high, showing a solid capital structure, but the ongoing losses are a concern.

Cash Flow

The company has consistently reported negative operating and free cash flows, pointing to challenges in generating cash from operations. The reliance on financing activities to support cash flow needs is notable. Despite this, the company has maintained a healthy cash position, mitigating some risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	1.53M	3.81M	5.04M
Gross Profit	-305.00K	0.00	-3.55M	-1.28M	2.82M	5.04M
EBITDA	-121.71M	-126.33M	-125.85M	-84.75M	-68.21M	-52.09M
Net Income	-116.51M	-129.87M	-116.80M	-81.88M	-68.21M	-52.89M
Balance Sheet
Total Assets	187.57M	240.32M	173.33M	266.21M	198.64M	118.97M
Cash, Cash Equivalents and Short-Term Investments	179.28M	231.06M	158.86M	249.07M	189.65M	111.51M
Total Debt	3.83M	4.49M	6.91M	8.99M	0.00	0.00
Total Liabilities	10.20M	50.42M	26.29M	21.04M	12.26M	14.79M
Stockholders Equity	177.37M	189.90M	147.03M	245.17M	186.38M	104.18M
Cash Flow
Free Cash Flow	-108.69M	-83.42M	-98.17M	-71.62M	-61.78M	-40.89M
Operating Cash Flow	-108.63M	-83.30M	-97.05M	-70.77M	-61.03M	-40.49M
Investing Cash Flow	-20.25M	52.70M	104.13M	-45.49M	-81.35M	-87.44M
Financing Cash Flow	143.82M	152.85M	1.45M	131.18M	141.48M	75.46M

RAPT Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.03
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RAPT, the sentiment is Positive. The current price of 8.03 is below the 20-day moving average (MA) of 8.28, above the 50-day MA of 7.75, and below the 200-day MA of 10.21, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 52.66 is Neutral, neither overbought nor oversold. The STOCH value of 35.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RAPT.

RAPT Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	59 Neutral	HK$15.37B	5.76	-7.44%	4.08%	11.55%	-28.15%
CGEN	57 Neutral	$160.84M	87.50	-24.22%	―	-23.40%	17.80%
SEER	55 Neutral	$128.28M	―	-24.73%	―	-1.02%	-8.59%
ADCT	51 Neutral	$267.78M	―	123.38%	―	10.49%	47.31%
NKTX	39 Underperform	$119.92M	―	-26.10%	―	―	30.76%
RAPT	39 Underperform	$134.93M	―	-75.60%	―	―	-2.29%
GLSI		$134.62M	―	-515.27%	―	―	―

RAPT Therapeutics Corporate Events

RAPT Therapeutics Announces Board Restructuring in 2025

On March 21, 2025, Dr. Wendye R. Robbins informed RAPT Therapeutics’ Board of Directors that she will not seek re-election at the company’s 2025 annual meeting, marking the end of her tenure. Subsequently, on March 25, 2025, the Board decided to reduce its size from six to five members, effective at the annual meeting.